Eli Lilly to Acquire Dermira for $1.1B

Share this


Eli Lilly to Acquire Dermira for $1.1B


  • Lilly acquires Dermira in all-cash transaction making total deal value ~$1.1B at $18.75/share representing premium of 86% to the 60-day volume-weighted average trading price of Dermira's stock ending on January 9- 2020- with expected closure of agreement in Q1’20
  • The focus of the acquisition is to expand Eli Lilly’s immunology pipeline with the addition of Dermira’s P-III candidate- Lebrikizumab and its dermatology marketed portfolio with Qbrexza (glycopyrronium) cloth
  • Lebrikizumab is a mAb targeted to bind IL-13 with very high affinity- preventing the formation of IL-13Rα1/IL-4Rα heterodimer complex targeted for mod-to-sev atopic dermatitis in adolescent and adult. Qbrexza cloth is FDA approved medicated cloth to treat primary axillary hyperhidrosis (uncontrolled excessive underarm sweating)

Click here to read full press release/ article

 Ref: PRNewswire | Image: Eli Lilly

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions